- Home
- GHG vs OMER Comparison
GHG vs OMER Comparison
Compare GHG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- OMER
- Stock Information
- Founded
- GHG 2004
- OMER 1994
- Country
- GHG China
- OMER United States
- Employees
- GHG N/A
- OMER N/A
- Industry
- GHG Hotels/Resorts
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- OMER Health Care
- Exchange
- GHG Nasdaq
- OMER Nasdaq
- Market Cap
- GHG 202.0M
- OMER 188.1M
- IPO Year
- GHG 2018
- OMER 2009
- Fundamental
- Price
- GHG $2.33
- OMER $3.83
- Analyst Decision
- GHG
- OMER Strong Buy
- Analyst Count
- GHG 0
- OMER 5
- Target Price
- GHG N/A
- OMER $18.00
- AVG Volume (30 Days)
- GHG 26.7K
- OMER 1.2M
- Earning Date
- GHG 08-14-2025
- OMER 08-06-2025
- Dividend Yield
- GHG 4.27%
- OMER N/A
- EPS Growth
- GHG N/A
- OMER N/A
- EPS
- GHG 0.15
- OMER N/A
- Revenue
- GHG $184,055,595.00
- OMER N/A
- Revenue This Year
- GHG $19.02
- OMER N/A
- Revenue Next Year
- GHG $8.26
- OMER $3,446.91
- P/E Ratio
- GHG $15.77
- OMER N/A
- Revenue Growth
- GHG N/A
- OMER N/A
- 52 Week Low
- GHG $1.93
- OMER $2.95
- 52 Week High
- GHG $3.40
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- GHG 51.67
- OMER 56.22
- Support Level
- GHG $2.14
- OMER $3.58
- Resistance Level
- GHG $2.78
- OMER $3.91
- Average True Range (ATR)
- GHG 0.16
- OMER 0.33
- MACD
- GHG -0.01
- OMER 0.07
- Stochastic Oscillator
- GHG 29.87
- OMER 52.74
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.